Phoebe Harvey

Company: Zymeworks

Job title: Medical Director, Clinical Research

Seminars:

Exploring Zanidatamab (ZW25): A Bispecific Antibody with Potential to be the Next Foundational Treatment for HER2-Experssing Cancers 3:30 pm

• Zanidatamab is a humanized, bispecific, IgG1-like antibody directed against the juxtamembrane domain (ECD4) and the dimerization domain (ECD2) of HER2 • Zanidatamab’s unique binding properties result in: receptor clustering, internalization, and downregulation; inhibition of growth factor-dependent and independent tumor cell proliferation; antibody-dependent cellular cytotoxicity and phagocytosis, and complement-dependent cytotoxicity • Zanidatamab has demonstrated durable…Read more

day: Day One